Baricitinib is a Janus kinase (JAK) inhibitor which is thought to inhibit several cytokines associated with PBC including Type 1 interferon, Interleukin 12, and Interleukin 23 [4]. This evidence concerns the gene IL37 and primary biliary cholangitis.